Please login to the form below

Xtandi

This page shows the latest Xtandi news and features for those working in and with pharma, biotech and healthcare.

J&J puts pressure on rivals with new Erleada okay in prostate cancer

FDA previously granted priority review in this indication. Johnson &Johnson has bagged an FDA approval for Erleada in metastatic castration-sensitive prostate cancer (mCSPC), gaining an advantage over main rival Xtandi ... Androgen inhibitor Erleada

Latest news

Trial backs role for Lynparza in second-line prostate cancer

In the 340-patient trial, Lynparza was compared to hormonal treatment with Pfizer’s Xtandi (enzalutamide) or Johnson &Johnson’s Zytiga (abiraterone acetate) in this second-line setting, focusing on patients ... previously treated with Zytiga,
Bayer bags FDA nod for early prostate cancer drug darolutamide

now subject to generic competition – as well as Pfizer/Astellas’ Xtandi (enzalutamide). ... Zytiga is only approved for metastatic CRPC and, as Xtandi and Erleada were only approved for non-metastatic CRPC in the last few months, Nubeqa has an
Pfizer adds Array to cancer arsenal with $11bn acquisition

cancers, where it has the blockbusters Ibrance and the Astellas co-marketed prostate cancer treatment Xtandi. ... The 2016 Medivation buyout saw its value drop when Xtandi failed to live up to expectations, and a late stage PARP inhibitor failed in phase
Bayer gains FDA priority review for prostate cancer drug

Once approved, the drug will go up against Johnson &Johnson’s Zytiga (with the first generics now reaching the market), its follow-up Erleada, and Pfizer/Astellas' Xtandi. ... Darolutamide won’t have an easy time competing in against these products,
Bayer, Orion prep challenge in prostate cancer market

Astellas said in its latest results statement that Xtandi made around $2.2bn in the first nine months of fiscal 2018/19, while J&J banked around $3.5bn from Zytiga ... Pfizer and Astellas have just reported positive results from the ARCHES trial of

More from news
Approximately 29 fully matching, plus 38 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

Analysts believe the drug could achieve peak sales of around $1.7bn, but will face fierce competition from the likes of Pfizer and Astellas’ established Xtandi. ... It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and
Deal Watch August 2016

35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.
Deal Watch May 2016

The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
Deal Watch March 2016

Only one other deal had an upfront value of more than $1bn: the sale by UCLA to Royalty Pharma of its royalty rights to Xtandi with a cash payment of ... Research collaboration. $2, 258. UCLA/ Royalty Pharma. Xtandi – androgen receptor inhibitor.
Astellas: Ten years young

Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide). ... There it is currently conducting a series of investigations in breast cancer to assess

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

Dendreon appoints new R&D lead

Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
Astellas promotes John Demaree

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
Astellas makes senior EMEA appointments

Both men are veterans of Astellas. Dew joined the company in 2006 as senior manager business development and has worked on major products such as Xtandi.
Astellas poaches new oncology head from Takeda

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Account Manager – Healthcare advertising: Salary TBC

Senior Medical Writer: Competitive salary plus benefits

Client Services Director- Flexible Working: Negotiable

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Director – UK Office: Excellent salary and benefits

Events Executive: DOE

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...